| Sejal Dave, MD | |
|
2711 X Ray Dr Ste 3701, Gastonia, NC 28054 | |
| (980) 834-9600 | |
| (980) 834-9605 |
| Full Name | Sejal Dave |
|---|---|
| Gender | Female |
| Speciality | Hematology/oncology |
| Experience | 23 Years |
| Location | 2711 X Ray Dr Ste 3701, Gastonia, North Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124234901 | NPI | - | NPPES |
| 036112168 | Medicaid | IL |
| Facility Name | Location | Facility Type |
|---|---|---|
| Carolinas Medical Center/behav Health | Charlotte, NC | Hospital |
| Atrium Health Union | Monroe, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Charlotte-mecklenburg Hospital Authority | 2961310685 | 488 |
| The Charlotte-mecklenburg Hospital Authority | 2961310685 | 488 |
News Archive
The US Health and Human Services administration announced $320 million in new grants under the Affordable Care Act (ACA) to strengthen the healthcare workforce in America. Florida alone will receive more than $11 million in grant funding.
Aeterna Zentaris Inc. today announced that final Phase 2 data demonstrated that the combination of perifosine, its oral AKT inhibitor, and sorafenib, was well tolerated by heavily pretreated patients with relapsed/refractory lymphomas.
The U.S. Food and Drug Administration (FDA) yesterday in a press release informed about the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) who have previously failed with one or more treatment. This is the first drug that the FDA has given its approval to in this disease condition.
Avicena Group, Inc. has announced that it has filed a composition of matter patent application with the United States Patent and Trademark Office to cover potential treatments for Parkinson's disease, a progressive neurodegenerative disease.
After treatment, 38.1 percent of patients with head and neck cancer who were employed at the time of cancer diagnosis reported discontinuing work because of their cancer and treatment, according to a report in the May issue of Archives of Otolaryngology-Head & Neck Surgery.
› Verified 8 days ago
| Entity Name | Caromont Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356314272 PECOS PAC ID: 3577476258 Enrollment ID: O20031201000070 |
News Archive
The US Health and Human Services administration announced $320 million in new grants under the Affordable Care Act (ACA) to strengthen the healthcare workforce in America. Florida alone will receive more than $11 million in grant funding.
Aeterna Zentaris Inc. today announced that final Phase 2 data demonstrated that the combination of perifosine, its oral AKT inhibitor, and sorafenib, was well tolerated by heavily pretreated patients with relapsed/refractory lymphomas.
The U.S. Food and Drug Administration (FDA) yesterday in a press release informed about the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) who have previously failed with one or more treatment. This is the first drug that the FDA has given its approval to in this disease condition.
Avicena Group, Inc. has announced that it has filed a composition of matter patent application with the United States Patent and Trademark Office to cover potential treatments for Parkinson's disease, a progressive neurodegenerative disease.
After treatment, 38.1 percent of patients with head and neck cancer who were employed at the time of cancer diagnosis reported discontinuing work because of their cancer and treatment, according to a report in the May issue of Archives of Otolaryngology-Head & Neck Surgery.
› Verified 8 days ago
| Entity Name | The Charlotte-mecklenburg Hospital Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669738829 PECOS PAC ID: 2961310685 Enrollment ID: O20100309000605 |
News Archive
The US Health and Human Services administration announced $320 million in new grants under the Affordable Care Act (ACA) to strengthen the healthcare workforce in America. Florida alone will receive more than $11 million in grant funding.
Aeterna Zentaris Inc. today announced that final Phase 2 data demonstrated that the combination of perifosine, its oral AKT inhibitor, and sorafenib, was well tolerated by heavily pretreated patients with relapsed/refractory lymphomas.
The U.S. Food and Drug Administration (FDA) yesterday in a press release informed about the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) who have previously failed with one or more treatment. This is the first drug that the FDA has given its approval to in this disease condition.
Avicena Group, Inc. has announced that it has filed a composition of matter patent application with the United States Patent and Trademark Office to cover potential treatments for Parkinson's disease, a progressive neurodegenerative disease.
After treatment, 38.1 percent of patients with head and neck cancer who were employed at the time of cancer diagnosis reported discontinuing work because of their cancer and treatment, according to a report in the May issue of Archives of Otolaryngology-Head & Neck Surgery.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sejal Dave, MD 2711 X Ray Dr Ste 3701, Gastonia, NC 28054-7491 Ph: (980) 834-9600 | Sejal Dave, MD 2711 X Ray Dr Ste 3701, Gastonia, NC 28054 Ph: (980) 834-9600 |
News Archive
The US Health and Human Services administration announced $320 million in new grants under the Affordable Care Act (ACA) to strengthen the healthcare workforce in America. Florida alone will receive more than $11 million in grant funding.
Aeterna Zentaris Inc. today announced that final Phase 2 data demonstrated that the combination of perifosine, its oral AKT inhibitor, and sorafenib, was well tolerated by heavily pretreated patients with relapsed/refractory lymphomas.
The U.S. Food and Drug Administration (FDA) yesterday in a press release informed about the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) who have previously failed with one or more treatment. This is the first drug that the FDA has given its approval to in this disease condition.
Avicena Group, Inc. has announced that it has filed a composition of matter patent application with the United States Patent and Trademark Office to cover potential treatments for Parkinson's disease, a progressive neurodegenerative disease.
After treatment, 38.1 percent of patients with head and neck cancer who were employed at the time of cancer diagnosis reported discontinuing work because of their cancer and treatment, according to a report in the May issue of Archives of Otolaryngology-Head & Neck Surgery.
› Verified 8 days ago
Louise Zhou, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2711 X Ray Dr Ste 3701, Gastonia, NC 28054 Phone: 980-834-9600 Fax: 980-834-9605 | |
Anthony R Arn, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2555 Court Dr, Suite 300, Gastonia, NC 28054 Phone: 704-868-3256 Fax: 704-868-5870 | |
Douglas A Nigbor, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2544 Court Dr, Ste F, Gastonia, NC 28054 Phone: 704-864-8302 Fax: 704-864-0228 | |
Ajaykumar Narandas Patel, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2525 Court Dr, Gastonia, NC 28054 Phone: 704-834-2000 Fax: 704-834-2500 | |
Dr. Yi Zhang, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 2544 Court Dr Ste F, Gastonia, NC 28054 Phone: 704-864-8302 Fax: 704-864-0228 | |
Dr. Shawnya Ayers Gore, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1867 Remount Rd, Suite D, Gastonia, NC 28054 Phone: 704-854-8799 Fax: 704-854-8803 | |
Richard Alan Fricker, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 2240 Remount Rd, Gastonia, NC 28054 Phone: 704-671-5344 Fax: 704-671-5331 |